SBMP - disrupting the manufacturing of biological drugs through a ground-breaking nanotechnology-based microcarrierbroad
SBMP-microcarrier · Horizon Europe grant · 2022-10-01–2024-09-30
EC contribution
Total cost
Beneficiaries
About the data
Source: CORDIS (official EU open data), Horizon Europe. Framework HORIZON · call HORIZON-EIC-2022-ACCELERATOR-01 · scheme HORIZON-EIC-ACC-BF · topic HORIZON-EIC-2022-ACCELERATOROPEN-01. CORDIS record →
Objective
Cellevate proposes a completely novel type of nanofibrous microcarriers for adherent cell culture in bioreactors based on the proprietary Superior Biologics Manufacturing Platform (SBMP). It is a game-changing deep-tech innovation for the biopharmaceutical industry. SBPM-microcarriers are highly customizable, faithfully replicate the 3D extracellular environment found in the human body, and provide a 60 times larger area for cell growth compared to competitive solutions. The unique scaffold properties are a result of a patent-pending nanofiber scaffold production technology (PCT/EP2020/081958) which creates networks of polymer nanofibers that can be handled in a liquid form, unachievable by competing solutions. By offering high yields and ensuring the optimal conditions for human cell growth, SBMP-microcarriers have the potential to transform the biopharmaceutical market by pushing the limits of today’s biological drugs production to an unachievable level of quality and efficiency.
Beneficiaries (1)
| Organisation | Country | Role | EC contribution | SME |
|---|---|---|---|---|
| CELLEVATE AB | SE | coordinator | €2,485,858 | Yes |
Get the DFM funding briefing — free
New EU defence calls, tenders and awards in your inbox.
Defence Finance Monitor is an analytical and informational product. Grant data is official CORDIS; payment and subscription happen on DFM Analysis.